What are the attributes of desmopressin vasopressin analog for the treatment of hemophilia A?

Updated: Apr 08, 2020
  • Author: Douglass A Drelich, MD; Chief Editor: Srikanth Nagalla, MBBS, MS, FACP  more...
  • Print

Desmopressin vasopressin analog, or 1-deamino-8-D-arginine vasopressin (DDAVP), has the following attributes:

  • Depending on baseline level and goal factor level, may be considered the treatment of choice for mild and moderate hemophilia A

  • Not effective in the treatment of severe hemophilia

  • Can be intravenously administered at a dose of 0.3 mcg/kg of body weight in the inpatient setting (Canadian labeling recommends maximum dose of 20 mcg).

  • Peak effect is observed in 30-60 minutes

  • DDAVP leads to free water retention, which can lead to hyponatremia

  • A concentrated DDAVP intranasal spray is available for outpatient use

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!